REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 10, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-09

Reporting Person: Tessier-Lavigne Marc (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-09	Common Stock	M	3784	$371.4	Acquired	5862	Direct
2021-12-09	Common Stock	S	3784	$665.0	Disposed	2078	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-09	Non-Qualified Stock Option (right to buy)	$371.4	M	3784	Disposed	2029-01-02	Common Stock (3784)	Direct

Footnotes

F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).

F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.